

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Erythropoiesis Stimulating Agents (ESAs) *For Non-Dialysis Use*

This form is to be completed ONLY if the patient is self-administering

Drug Requested: (check one below)

<input type="checkbox"/> Aranesp [®] (darbepoetin alfa)	<input type="checkbox"/> Epogen [®] (epoetin alfa)	<input type="checkbox"/> Mircera [®] (methoxy polyethylene glycol-epoetin beta)
<input type="checkbox"/> Procrit [®] (epoetin alfa)	<input type="checkbox"/> Retacrit [™] (epoetin alfa-epbx)	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight: _____ Date: _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

(Continued on next page)

Diagnosis: Anemia Due to Chronic Kidney Disease

Initial Authorization: 6 months

- Member has a documented diagnosis of anemia due to chronic kidney disease (CKD)
- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member must meet **ONE** of the following hemoglobin requirements:
 - Member is an adult with a hemoglobin level <10 g/dL
 - Member is a pediatric patient who is symptomatic with a hemoglobin level <11 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
- Member is **NOT** receiving hemodialysis
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Diagnosis: Anemia Due to Chronic Kidney Disease

Reauthorization: 6 months. Check below all that apply. All criteria must be checked for approval. To support each line checked, all documentation, including (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level \leq 12 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%

Diagnosis: Anemia Due to Myelosuppressive Chemotherapy

Length of Authorization: 6 months

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member must meet **ONE** of the following hemoglobin requirements:
 - Member is an adult with a hemoglobin level <10 g/dL
 - Member is a pediatric patient who is symptomatic with a hemoglobin level <11 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
- Member is being treated with myelosuppressive chemotherapy and provider has noted member's current treatment regimen: _____
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

(Continued on next page)

Diagnosis: Anemia Due to Myelodysplastic Syndrome (MDS)

Initial Authorization: 6 months

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level <10 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
 - Member's serum erythropoietin level \leq 500 milliunits/mL
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Diagnosis: Anemia Due to Myelodysplastic Syndrome (MDS)

Reauthorization: 12 months. Check below all that apply. All criteria must be checked for approval. To support each line checked, all documentation, including (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level <12 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
 - Member's serum erythropoietin level \leq 500 milliunits/mL

Diagnosis: Anemia of Prematurity

Length of Authorization: 6 months

- Documentation of **ALL** the following must be submitted:
 - Medication will be used in combination with iron supplementation
 - Member must meet **ONE** of the following:
 - Member's birth weight <1500 grams
 - Member's gestational age <33 weeks

Diagnosis: Anemia Due to Myelosuppressive Medication Regimen for HIV

Initial Authorization: 6 months

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member must meet **ONE** of the following hemoglobin requirements:
 - Member is an adult with a hemoglobin level <10 g/dL
 - Member is a pediatric patient who is symptomatic with a hemoglobin level <11 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)

- Member's transferrin saturation (TSAT) \geq 20%
- Member's serum erythropoietin level \leq 500 milliunits/mL
- Member is being treated with an HIV medication regimen that includes zidovudine (\leq 4200mg/week)
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Diagnosis: Anemia Due to Myelosuppressive Medication Regimen for HIV

Reauthorization: 6 months. Check below all that apply. All criteria must be checked for approval. To support each line checked, all documentation, including (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- Member continues to receive an HIV medication regimen that includes zidovudine (\leq 4200 mg/week)
- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level \leq 12 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
 - Member's serum erythropoietin level \leq 500 milliunits/mL

Diagnosis: Anemia Due to Myelosuppressive Medication Regimen for Hepatitis C

Initial Authorization: 6 months

- Member has a documented diagnosis of anemia
- Member is being treated with a myelosuppressive regimen (e.g., ribavirin with interferon or peginterferon) for the treatment of Hepatitis C
- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member must meet **ONE** of the following hemoglobin requirements:
 - Member is an adult with a hemoglobin level $<$ 10 g/dL
 - Member is a pediatric patient who is symptomatic with a hemoglobin level $<$ 11 g/dL
 - Member's serum ferritin \geq 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) \geq 20%
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Diagnosis: Anemia Due to Myelosuppressive Medication Regimen for Hepatitis C

Reauthorization: 6 months. Check below all that apply. All criteria must be checked for approval. To support each line checked, all documentation, including (lab results, diagnostics, and/or chart notes) must be provided or request may be denied.

- Member continues to receive a myelosuppressive regimen for the treatment of Hepatitis C

- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level ≤ 12 g/dL
 - Member's serum ferritin ≥ 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) $\geq 20\%$

Diagnosis: Reduction of Allogenic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery

Length of Authorization: 3 months

- Requested drug will be used to decrease the need for blood transfusion in a surgery patient
- Member is scheduled to undergo surgery within the next three (3) months
- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's hemoglobin level < 13 g/dL
 - Member's serum ferritin ≥ 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) $\geq 20\%$
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Diagnosis: All Other Indications

Length of Authorization: 6 months

- Member's diagnosis of anemia and/or risk factors for development of anemia must be noted in submitted chart notes for medical necessity approval
- Provider must document requested length of therapy: _____
- Provider must submit documentation of **ALL** the following test results obtained **within the last 30 days**:
 - Member's current hemoglobin level: _____
 - Member's serum ferritin ≥ 100 ng/mL (mcg/L)
 - Member's transferrin saturation (TSAT) $\geq 20\%$
 - If applicable, any other test results to support medical necessity approval
- All other causes of anemia have been ruled out (e.g., iron, vitamin B12 or folate deficiency, hemolysis)

Medication being provided by Specialty Pharmacy – Proprium Rx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****